| Autor: |
Xi, Weiwei, Zhao, Xuming, Wang, Boya, Zhu, Yichen, Li, Hua, Xiaohan, Ren |
| Zdroj: |
International Journal of Clinical Practice; 8/21/2024, Vol. 2024, p1-13, 13p |
| Abstrakt: |
Diabetes nephropathy (DN) is increasingly recognized as a critical complication in individuals with diabetes and a significant contributor to end‐stage renal disease (ESRD). Bailing capsules, which contain fermented cordyceps mycelium, are commonly utilized in treating various kidney disorders, including DN in clinical practice. This review aims to comprehensively detail the pharmacologically active components of Bailing, its mechanisms of action, and its clinical usage. By employing network pharmacology, we delve into the possible pathways Bailing impacts DN treatment. Current studies suggest that Bailing's efficacy in DN primarily involves mechanisms related to lipid and atherosclerosis, cancer pathways, and small‐cell lung cancer. Key active ingredients in Bailing that contribute to its therapeutic effects include arachidonic acid, linalyl acetate, β‐sitosterol, and CLR. Furthermore, for literature selection in this review, we integrated GPT‐4 with bias analysis coprocessing. This evaluation provides a foundational understanding and direction for future research into the use of Bailing as a novel treatment for DN. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text